77940-92-2
Chemical Structure
(R)-Nimodipine
Synonym(s): (R)-BAY-e 9736
- CAS No.: 77940-92-2
- Formula:C21H26N2O7
- Molecular Weight:418.44
InChIKey: UIAGMCDKSXEBJQ-LJQANCHMSA-N
SMILES: O=C(C1=C(C)NC(C)=C(C(OC(C)C)=O)[C@@H]1C2=CC=CC([N+]([O-])=O)=C2)OCCOC
Biological Activity: (R)-Nimodipine ((R)-BAY-e 9736) is an orally active, blood-brain barrier-permeable L-type calcium channel blocker with an IC50 of 5 nM. (R)-Nimodipine inhibits corticosterone release by blocking calcium channels on the hypothalamic-pituitary-adrenal axis, thereby reversing immobilization stress-induced memory impairment and behavioral abnormalities. (R)-Nimodipine is widely used in studies related to aneurysmal subarachnoid hemorrhage, cerebral ischemia, epilepsy, age-related degenerative neurological diseases, and alcohol intoxication[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(R)-Nimodipine | 99.87% | (R)-Nimodipine ((R)-BAY-e 9736) is an orally active, blood-brain barrier-permeable L-type calcium channel blocker with an IC50 of 5 nM. (R)-Nimodipine inhibits corticosterone release by blocking calcium channels on the hypothalamic-pituitary-adrenal axis, thereby reversing immobilization stress-induced memory impairment and behavioral abnormalities. (R)-Nimodipine is widely used in studies related to aneurysmal subarachnoid hemorrhage, cerebral ischemia, epilepsy, age-related degenerative neurological diseases, and alcohol intoxication. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Scriabine A, et al. Pharmacological basis for the use of nimodipine in central nervous system disorders. FASEB J. 1989;3(7):1799-1806. [Content Brief]
- [2]. Kumar N, et al. Anti-stress effects of cilnidipine and nimodipine in immobilization subjected mice. Physiol Behav. 2012;105(5):1148-1155. [Content Brief]
- [3]. Carlson AP, et al. Nimodipine Reappraised: An Old Drug With a Future. Curr Neuropharmacol. 2020;18(1):65-82. [Content Brief]
Keywords
